Monitor upcoming trial data for PAS-004 (NF1 Phase 1/1b) as the key catalyst; the CMO appointment adds relevant MEK inhibitor experience but provides no immediate trading signal.
Price Chart
Executive Summary
Pasithea Therapeutics appointed Dr. Kartik Krishnan as Chief Medical Officer effective May 1, 2026, and granted substantial stock options to executives, employees, and directors at $0.841 per share. This is a routine organizational change with no financial results or guidance provided.
Key Facts
- Kartik Krishnan appointed CMO effective May 1, 2026; base salary $500k plus up to 40% annual bonus.
- Stock option grants: CEO 1,756,069 shares; CFO 1,129,323; CMO 1,129,323; employees 1,239,323; directors 611,132 total. All at $0.841 exercise price.
- Options vest 33% year 1, remaining quarterly over 2 years; full vest on change of control.
- No departures, financial results, or guidance were disclosed.
Financial Impact
No direct financial impact disclosed; option grants are standard compensation.
Risk Factors
- Potential dilution from option exercises (up to ~5.86M shares).
- Clinical trial risks for PAS-004; no efficacy data yet.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-051681 |
| Document: ea0288864-8k_pasithea.htm | 0001213900-26-051681 |
| Document: ea028886401ex99-1.htm | 0001213900-26-051681 |
| Document: 0001213900-26-051681-index-headers.html | 0001213900-26-051681 |
| Document: 0001213900-26-051681-index.html | 0001213900-26-051681 |
| Document: 0001213900-26-051681.txt | 0001213900-26-051681 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | 8-K | $0.007400 $0.002700 | ▲ +63.51% | ▲ +63.98% | — |
May 4, 2026 25w ago | 8-K | $0.0109 $0.0109 | · 0.00% | ▼ −1.98% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers